Tissue Dynamics公司与Galmed制药有限公司（纳斯达克代码：GLMD）宣布达成战略合作，将共同构建专注于人类疾病模型的慢性心脏纤维化研究平台。该合作旨在加速基于Aramchol（Galmed公司核心候选药物）的新型治疗方案开发进程。
此次合作将结合Tissue Dynamics在人体组织动态监测领域的专长与Galmed在代谢性疾病治疗药物研发方面的经验，重点关注心脏纤维化这一影响全球数百万患者的慢性疾病领域。通过建立更贴近人类病理生理特征的实验平台，双方期望提升药物研发效率，为心血管疾病患者提供更精准的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.